Artery Graft Articles & Analysis: Older
13 news found
Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG – which is a coronary artery bypass graft; and its pulmonary heart valve, which was the first ever synthetic valve to enter a pivotal trial (Xplore2/Pivotal) in July this year. ...
The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, synthetic blood vessel device that turns into a living blood vessel when colonised by patient’s own ...
” Xeltis’ devices are vascular grafts and heart valves designed to turn into living valves and vessels by harnessing the body’s natural healing process and by facilitating tissue formation once implanted. ...
An estimated one million people suffer from refractory angina in the United States. About Coronary Artery Bypass Graft Surgery (CABG) CABG is a procedure used to treat coronary artery disease — the narrowing or blockage of the blood vessels that supply oxygen and nutrients to the heart muscle. During CABG, a healthy ...
In addition to its restorative pulmonary valve, Xeltis has developed the first-ever restorative synthetic coronary artery bypass graft (CABG) to have shown successful long-term results in long preclinical trials and the first-ever restorative synthetic vascular access graft for patients that need ...
Coronary bifurcation lesions are prevalent in about 30% of Coronary Artery Bypass Grafting procedures and about 20% of Percutaneous Coronary Intervention procedures. ...
The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply. ...
The disease that Bilix has targeted is ischemic reperfusion injury caused by organ transplantation, myocardial infarction, coronary artery bypass grafting, and stroke. In the case of myocardial infarction, it occurs after a patient undergoes a stent procedure. ...
Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial with Elafin in ECS is in preparation. ...
Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial with Elafin in ECS is in preparation. ...
About Heartcel Heartcell is an allogeneic cell therapy containing off-the-shelf immunomodulatory progenitor (iMP) cells engineered to regenerate the heart. iMPs are administered during coronary artery bypass graft (CABG) surgery by direct injection around the cardiac scar that is to be regenerated. iMP cells have been designated an Advanced Therapeutic Medicinal ...
Heartcel, Celixir’s lead investigational cardiac regenerative medicine, is a tissue engineered medicine comprising allogeneic (off-the-shelf) immunomodulatory progenitor (iMP) cells and is designated as an advanced therapeutic medicinal product (ATMP) by the European Medicines Agency. iMP cells are a novel cell type engineered to reduce heart scarring and regenerate the heart in patients ...
Healionics Corporation has been awarded a $150,000 Small Business Innovation Research (SBIR) contract from the Department of Defense (DOD) to demonstrate feasibility for an improved vascular graft design. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project. Titled, “Biointegrated Synthetic ...